Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations



    ATIR(TM) Data Presented at the Annual EBMT Presidential Symposium

    AMSTERDAM, April 8 /CNW/ - Biopharmaceutical company Kiadis Pharma
reported preliminary clinical data on ATIR(TM) showing its potential in
mismatched bone marrow transplantations. Data was presented by the company's
principal investigator Dr. Denis Claude Roy during the prestigious
Presidential Symposium at the Annual European Bone Marrow Transplantation
meeting (EBMT) in Goteborg, Sweden, on Monday, March 30, 2009. Only the 6
highest ranked presentations, representing the most promising new developments
in the transplantation field, were selected for this Symposium.
    ATIR(TM), a donor lymphocyte cell based preparation depleted of
allo-reactive T-cells, is under development to prevent acute Graft versus Host
Disease (GvHD) and allow for early immune reconstitution following a bone
marrow transplantation with a fully mismatched (haplo-identical) donor.
    Dr. Roy's presentation of clinical results from 19 end stage blood cancer
patients with high risk leukemia and/or lymphoma using ATIR(TM) was very well
received. These patients, each of whom did not have a matched donor available,
were treated in a phase I/II dose escalating study with ATIR(TM) in a
mismatched transplantation setting. No immune suppressants were used, which is
in contrast to conventional transplant procedures. Nevertheless, no cases of
severe grade III/IV acute GvHD occurred after ATIR(TM) infusion. Furthermore,
the clinical data showed a reduction in the frequency of infectious episodes
in the cohorts treated with the higher doses of ATIR(TM), as compared to the
low dose cohorts. To date, patients in the higher dose cohorts show high
survival rates (75%) with no transplant related mortality (TRM).
    These results show that the selective depletion of allo-reactive T-cells
in the ATIR(TM) cell based product by the proprietary photo-sensitizing agent
TH9402 is highly effective and can result in fast and adequate immune
reconstitution in combination with the prevention of acute GvHD in bone marrow
transplantations using a mismatched donor.
    Dr. Denis-Claude Roy, Head of Stem Cell Therapy of the Hospital
Maisonneuve-Rosemont, Montreal, Canada says: "These are fascinating results,
demonstrating the feasibility of performing mismatched transplantations with
an ATIR(TM) infusion. These results may give hope to patients who currently
cannot be treated because of limited donor availability. In the future
ATIR(TM) may allow mismatched transplantations to be performed in virtually
all patients who cannot find a donor thereby improving the outcome of the
whole procedure."
    Dr. Manja Bouman, CEO of Kiadis Pharma, says: "Kiadis Pharma is pleased
with the election of our ATIR(TM) data to be presented at the Presidential
Symposium of the EBMT. It shows the interest in our approach by the medical
community. On the basis of these highly encouraging results we are currently
preparing for a multinational registration study with ATIR(TM) in mismatched
transplantation procedures."

    Go to http://www.kiadis.com for the complete press release






For further information:

For further information: Kiadis Pharma B.V., Eefje Simpelaar, Director
Communications, Email: e.simpelaar@kiadis.com, Tel: +31-20-3140250, Mob:
+31-6-10829344

Organization Profile

KIADIS PHARMA

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890